Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 48-57 , January 2008

Intensity-Modulated Radiation Therapy: Supportive Data for Prostate Cancer

  • Oren Cahlon, MD

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • ,
  • Margie Hunt, MS

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • ,
  • Michael J. Zelefsky, MD

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • Corresponding Author InformationAddress reprint requests to Michael J. Zelefsky, MD, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY 10065.

References 

  1. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  2. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years’ follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427–435
  3. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  4. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904–3911
  5. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  6. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  7. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689
  8. Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1074–1081
  9. Zelefsky MJ, Hunt MA, Fuks Z, et al. Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66(suppl 1):S9;(abstr)
  10. Chism DB, Horwitz EM, Hanlon AL, et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 2003;55:71–77
  11. Lawton C, Won M, Pilepich M, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21:935–939
  12. Smit WWG, Helle PPA, van Putten WWL, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23–29
  13. Ling CC, Burman C, Chui CS, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Physs. 1996;35:721–730
  14. De Meerleer GO, Vakaet LA, De Gersem WR, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int J Radiat Oncol Biol Phys. 2000;47:639–648
  15. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241–249
  16. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  17. Jani AB, Su A, Correa D, et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis. 2006;10:82–86
  18. De Meerleer GO, Fonteyne VH, Vakaet L, et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother Oncol. 2007;82:160–166
  19. Teh BS, Mai WY, Uhl BM, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys. 2001;49:705–712
  20. Vora SA, Wong WW, Schild SE, et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1053–1058
  21. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  22. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  23. Cahlon O, Zelefsky MJ, Shippy A, et al. Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes. Int J Radiat Oncol Biol Phys. 2006;66(suppl 1):S33;(abstr)
  24. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006;355:1583–1591
  25. Kupelian PA, Buchsbaum JC, Reddy CA, et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason <= 6, and pretreatment prostate-specific antigen <= 10). Int J Radiat Oncol Biol Phys. 2001;50:621–625
  26. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol. 2004;171:1132–1136
  27. Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 1991;21:537–547
  28. Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1074–1081
  29. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740–2746
  30. Hanks GE, Teshima T, Pajak TF. 20 years of progress in radiation oncology: Prostate cancer. Semin Radiat Oncol. 1997;7:114–120
  31. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460–2468
  32. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  33. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  34. Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys. 1998;41:501–510
  35. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–1046
  36. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  37. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007;83:31–41
  38. Beckendorf V, Guerif S, Le Prise E, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1056–1065
  39. Penson DF, Litwin MS. Quality of life after treatment for prostate cancer. Curr Urol Rep. 2003;4:185–195
  40. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–2247
  41. van Tol-Geerdink JJ, Stalmeier PFM, van Lin ENJT, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment?. J Clin Oncol. 2006;24:4581–4586
  42. Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys. 2007;69:656–661
  43. Namiki SS, Ishidoya SS, Tochigi TT, et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy. Jap J Clin Oncol. 2006;36:224–230
  44. Speight JL, Roach M. Advances in the treatment of localized Prostate Cancer: The role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. 2007;25:987–995
  45. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  46. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:765–771
  47. Liu Y-M, Shiau C-Y, Lee M-L, et al. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1113–1123
  48. Su AW, Jani A. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol Cancer Clin Trials. 2007;30:215–219
  49. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63:1262–1269
  50. Wang-Chesebro A, Xia P, Coleman J, et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:654–662
  51. Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk?. Eur Urol. 2007;52:973–982
  52. Brenner DJ, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398–406
  53. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7
  54. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83–88
  55. Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:1195–1203
  56. Schneider U, Lomax A, Besserer J, et al. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:892–897
  57. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  58. Zelefsky MJ, Fuks Z, Leibel SA, et al. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol. 2002;12:229–237
  59. Burman C, Chui CS, Kutcher G, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:863–873
  60. Ma L, Yu CX, Earl M, et al. Optimized intensity-modulated arc therapy for prostate cancer treatment. Int J Cancer. 2001;96:379–384
  61. Yu CX, Li XA, Ma L, et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys. 2002;53:453–463
  62. Curran B. Where goest the peacock?. Med Dosim. 2001;26:3–9
  63. Grigorov G, Kron T, Wong E, et al. Optimization of helical tomotherapy treatment plans for prostate cancer. Phys Med Biol. 2003;48:1933–1943
  64. Rodrigues G, Yartsev S, Chen J, et al. A comparison of prostate IMRT and helical tomotherapy class solutions. Radiother Oncol. 2006;80:374–377
  65. Pirzkall A, Carol MP, Pickett B, et al. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys. 2002;53:434–442
  66. Price RA, Hanks GE, McNeeley SW, et al. Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method. Int J Radiat Oncol Biol Phys. 2002;53:236–243
  67. Aoyama H, Westerly DC, Mackie TR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys. 2006;64:962–967
  68. Bortfeld T. Optimized planning using physical objectives and constraints. Semin Radiat Oncol. 1999;9:20–34
  69. Verhey LJ. Issues in optimization for planning of intensity-modulated radiation therapy. Semin Radiat Oncol. 2002;12:210–218
  70. Spirou SV, Chui CS. A gradient inverse planning algorithm with dose-volume constraints. Med Phys. 1998;25:321–333
  71. Spirou SV, Chui CS. Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators. Med Phys. 1994;21:1031–1041
  72. Skwarchuk MW, Jackson A, Zelefsky M, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer I: Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47:103–113
  73. Algan O, Hanks GE, Shaer AH. Localization of the prostatic apex for radiation treatment planning. Int J Radiat Oncol Biol Phys. 1995;33:925–930
  74. Milosevic M, Voruganti S, Blend R, et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: Comparison to computed tomography (CT) and urethrography. Radiother Oncol. 1998;47:277–284
  75. Roach MR, Faillace-Akazawa P, Malfatti C, et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35:1011–1018
  76. Rasch C, Barillot I, Remeijer P, et al. Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys. 1999;43:57–66
  77. Chen L, Price RA, Nguyen TB, et al. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. Phys Med Biol. 2004;49:5157–5170
  78. Zelefsky M, Crean D, Mageras GS, et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol. 1999;50:225–234
  79. Kuban DA, Dong L, Cheung R, et al. Ultrasound-based localization. Semin Radiat Oncol. 2005;15:180–191
  80. Balter JM, Sandler HM, Lam K, et al. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys. 1995;31:113–118
  81. Crook JM, Raymond Y, Salhani D, et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995;37:35–42
  82. Sandler HM, Bree RL, McLaughlin PW, et al. Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys. 1993;27:915–919
  83. Langen KM, Zhang Y, Andrews RD, et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys. 2005;62:1517–1524
  84. Létourneau D, Martinez AA, Lockman D, et al. Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients. Int J Radiat Oncol Biol Phys. 2005;62:1239–1246
  85. Moseley DJ, White EA, Wiltshire KL, et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 2007;67:942–953
  86. Martin JM, Rosewall T, Bayley A, et al: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (in press)

PII: S1053-4296(07)00079-3

doi: 10.1016/j.semradonc.2007.09.007

Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 48-57 , January 2008

Article Tools

* Image Usage & Resolution